← All trials
NCT05131841
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 4, 2021
- Primary completion
- Dec 30, 2022
- Completion date
- Dec 30, 2022
- First posted
- Nov 23, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Chinese Academy of Medical SciencesStudy director
- Proswell Medical CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.